XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders' Deficit - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total
Balance (in shares) at Dec. 31, 2022 73,104,692        
Balance at the beginning of the period at Dec. 31, 2022 $ 72 $ 2,305,020 $ 4,796 $ (2,656,974) $ (347,086)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 211,561        
Exercise of options   5,655     5,655
Restricted stock vesting and issuance (in shares) 695,781        
Restricted stock vesting and issuance, net $ 1       1
Share-based compensation expense   28,815     28,815
Receivable from investor   396     396
Net Income (Loss)       (138,959) (138,959)
Comprehensive (loss) income     (6,383)   (6,383)
Balance (in shares) at Mar. 31, 2023 74,012,034        
Balance at the end of the period at Mar. 31, 2023 $ 73 2,339,886 (1,587) (2,795,933) (457,561)
Balance (in shares) at Dec. 31, 2023 75,708,889        
Balance at the beginning of the period at Dec. 31, 2023 $ 75 2,466,233 (1,285) (3,283,578) (818,555)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 109,892        
Exercise of options   2,030     2,030
Restricted stock vesting and issuance (in shares) 835,179        
Restricted stock vesting and issuance, net $ 1       1
Share-based compensation expense   18,378     18,378
Receivable from investor   81     81
Net Income (Loss)       (91,576) (91,576)
Comprehensive (loss) income     (4,275)   (4,275)
Balance (in shares) at Mar. 31, 2024 76,653,960        
Balance at the end of the period at Mar. 31, 2024 $ 76 $ 2,486,722 $ (5,560) $ (3,375,154) $ (893,916)